CoChat

Time course of tolerance to the performance benefits of caffeine

Open access
Lara, Beatriz, Ruiz-Moreno, Carlos, Salinero, Juan José, Del Coso, Juan · 2019 · PLOS ONE

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

The ergogenic effect of acute caffeine ingestion has been widely investigated; however, scientific information regarding tolerance to the performance benefits of caffeine, when ingested on a day-to-day basis, is scarce. The aim of this investigation was to determine the time course of tolerance to the ergogenic effects of a moderate dose of caffeine. Eleven healthy active participants took part in a cross-over, double-blind, placebo-controlled experiment. In one treatment, they ingested 3 mg/kg/day of caffeine for 20 consecutive days while in another they ingested a placebo for 20 days. Each substance was administered daily in an opaque unidentifiable capsule, and the experimental trials started 45 min after capsule ingestion. Two days before, and three times per week during each 20-day treatment, aerobic peak power was measured with an incremental test to volitional fatigue (25 W/min) and aerobic peak power was measured with an adapted version of the Wingate test (15 s). In comparison to the placebo, the ingestion of caffeine increased peak cycling power in the incremental exercise test by ~4.0 ±1.3% for the first 15 days (P<0.05) but then this ergogenic effect lessened. Caffeine also increased peak cycling power during the Wingate test on days 1, 4, 15, and 18 of ingestion by ~4.9 ±0.9% (P<0.05). In both tests, the magnitude of the ergogenic effect of caffeine vs. placebo was higher on the first day of ingestion and then progressively decreased. These results show a continued ergogenic effect with the daily ingestion of caffeine for 15-18 days; however, the changes in the magnitude of this effect suggest progressive tolerance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0210275

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Experimental design of the investigation. Caffeine (3 mg/kg/day) or a placebo was administered for 20 consecutive days in a randomized order. Exercise performance was measured on day 0 (48 h before treatment) and on days 1, 4, 6, 8, 11, 13, 15, 18 and 20 with each protocol. Exercise performance assessment included a graded exercise test on a cycle ergometer to volitional fatigue and the 15-s Wingate test 45 min after the ingestion of the assigned capsule. Only on day 11 during each treatment, participants ingested the capsule after the end of the exercise.
Fig 1 Experimental design of the investigation. Caffeine (3 mg/kg/day) or a placebo was administered for 20 consecutive days in a randomized order. Exercise performance was measured on day 0 (48 h before treatment) and on days 1, 4, 6, 8, 11, 13, 15, 18 and 20 with each protocol. Exercise performance assessment included a graded exercise test on a cycle ergometer to volitional fatigue and the 15-s Wingate test 45 min after the ingestion of the assigned capsule. Only on day 11 during each treatment, participants ingested the capsule after the end of the exercise.CC BY · PubMed Central
Fig 2 Peak cycling power (Wmax) obtained during a graded exercise test with the administration of 3 mg/kg/day of caffeine or a placebo for 20 consecutive days. The upper panel depicts the effect size (± 90% confidence intervals) for all pairwise comparisons. Only effect sizes with a possible likelihood of difference (>25%) are categorized: (++++) most likely, (+++) very likely, (++) likely, (+) possibly. The lower panel depicts data presented as mean ± standard deviation. The data have been normalized with respect to the values obtained on day 0 of each treatment to provide a better comparison of the caffeine ergogenic effect in the studied variables. (*) Caffeine different from placebo for the same day, P < 0.05. (†) Different from day 0 within the same treatment, P < 0.05.
Fig 2 Peak cycling power (Wmax) obtained during a graded exercise test with the administration of 3 mg/kg/day of caffeine or a placebo for 20 consecutive days. The upper panel depicts the effect size (± 90% confidence intervals) for all pairwise comparisons. Only effect sizes with a possible likelihood of difference (>25%) are categorized: (++++) most likely, (+++) very likely, (++) likely, (+) possibly. The lower panel depicts data presented as mean ± standard deviation. The data have been normalized with respect to the values obtained on day 0 of each treatment to provide a better comparison of the caffeine ergogenic effect in the studied variables. (*) Caffeine different from placebo for the same day, P < 0.05. (†) Different from day 0 within the same treatment, P < 0.05.CC BY · PubMed Central
Fig 3 Maximal oxygen uptake (VO2max) obtained during a graded exercise test with the administration of 3 mg/kg/day of caffeine or a placebo for 20 consecutive days. The upper panel depicts the effect size (± 90% confidence intervals) for all pairwise comparisons. Only effect sizes with a possible likelihood of difference (>25%) are categorized: (++++) most likely, (+++) very likely, (++) likely, (+) possibly. The lower panel depicts data presented as mean ± standard deviation. The data have been normalized with respect to the values obtained on day 0 of each treatment to provide a better comparison of the caffeine ergogenic effect in the studied variables. (*) Caffeine different from placebo for the same day, P < 0.05. (†) Different from day 0 within the same treatment, P < 0.05.
Fig 3 Maximal oxygen uptake (VO2max) obtained during a graded exercise test with the administration of 3 mg/kg/day of caffeine or a placebo for 20 consecutive days. The upper panel depicts the effect size (± 90% confidence intervals) for all pairwise comparisons. Only effect sizes with a possible likelihood of difference (>25%) are categorized: (++++) most likely, (+++) very likely, (++) likely, (+) possibly. The lower panel depicts data presented as mean ± standard deviation. The data have been normalized with respect to the values obtained on day 0 of each treatment to provide a better comparison of the caffeine ergogenic effect in the studied variables. (*) Caffeine different from placebo for the same day, P < 0.05. (†) Different from day 0 within the same treatment, P < 0.05.CC BY · PubMed Central
Fig 4 Peak cycling power obtained during an adapted version of the Wingate test (all-out 15 s sprint) with the administration of 3 mg/kg/day of caffeine or a placebo for 20 consecutive days. The upper panel depicts the effect size (± 90% confidence intervals) for all pairwise comparisons. Only effect sizes with a possible likelihood of difference (>25%) are categorized: (++++) most likely, (+++) very likely, (++) likely, (+) possibly. The lower panel depicts data presented as mean ± standard deviation. The data have been normalized with respect to the values obtained on day 0 of each treatment to provide a better comparison of the caffeine ergogenic effect in the studied variables. (*) Caffeine different from placebo for the same day, P < 0.05. (†) Different from day 0 within the same treatment, P < 0.05.
Fig 4 Peak cycling power obtained during an adapted version of the Wingate test (all-out 15 s sprint) with the administration of 3 mg/kg/day of caffeine or a placebo for 20 consecutive days. The upper panel depicts the effect size (± 90% confidence intervals) for all pairwise comparisons. Only effect sizes with a possible likelihood of difference (>25%) are categorized: (++++) most likely, (+++) very likely, (++) likely, (+) possibly. The lower panel depicts data presented as mean ± standard deviation. The data have been normalized with respect to the values obtained on day 0 of each treatment to provide a better comparison of the caffeine ergogenic effect in the studied variables. (*) Caffeine different from placebo for the same day, P < 0.05. (†) Different from day 0 within the same treatment, P < 0.05.CC BY · PubMed Central
Fig 5 Mean cycling power obtained during an adapted version of the Wingate test (all-out 15 s sprint) with the administration of 3 mg/kg/day of caffeine or a placebo for 20 consecutive days. The upper panel depicts the effect size (± 90% confidence intervals) for all pairwise comparisons. Only effect sizes with a possible likelihood of difference (>25%) are categorized: (++++) most likely, (+++) very likely, (++) likely, (+) possibly. The lower panel depicts data presented as mean ± standard deviation. The data have been normalized with respect to the values obtained on day 0 of each treatment to provide a better comparison of the caffeine ergogenic effect in the studied variables. (*) Caffeine different from placebo for the same day, P < 0.05. (†) Different from day 0 within the same treatment, P < 0.05.
Fig 5 Mean cycling power obtained during an adapted version of the Wingate test (all-out 15 s sprint) with the administration of 3 mg/kg/day of caffeine or a placebo for 20 consecutive days. The upper panel depicts the effect size (± 90% confidence intervals) for all pairwise comparisons. Only effect sizes with a possible likelihood of difference (>25%) are categorized: (++++) most likely, (+++) very likely, (++) likely, (+) possibly. The lower panel depicts data presented as mean ± standard deviation. The data have been normalized with respect to the values obtained on day 0 of each treatment to provide a better comparison of the caffeine ergogenic effect in the studied variables. (*) Caffeine different from placebo for the same day, P < 0.05. (†) Different from day 0 within the same treatment, P < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 143

Metadata

Authors
Lara, B., Ruiz-Moreno, C., Salinero, J. J., & Del Coso, J.
Affiliations
Camilo José Cela University (ES)
Venue
PLOS ONE
Published
2019-01-23
Volume
14
Issue
1
Pages
e0210275
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2913413117
Cited by
142
References
45
Citations by year
2026: 11 · 2025: 20 · 2024: 10 · 2023: 11 · 2022: 23 · 2021: 23 · 2020: 28 · 2019: 15
FWCI
13.79
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • RUIdeRA - Institutional University Repository (University of Castilla-La Mancha) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Sports Performance and Training
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
Keywords
caffeine, caffeine tolerance, ergogenic aids, aerobic performance, incremental exercise test, Wingate test
MeSH terms
Adult, Central Nervous System Stimulants, Caffeine, Double-Blind Method, Drug Tolerance, Fatigue, Female, Humans, Male, Oxygen Consumption, Exercise, Cross-Over Studies, Performance-Enhancing Substances

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Time course of tolerance to the performance benefits of caffeine. https://app.cochat.ai/papers/10.1371/journal.pone.0210275
The paper
Lara, B., Ruiz-Moreno, C., Salinero, J. J., & Del Coso, J. (2019). Time course of tolerance to the performance benefits of caffeine. PLOS ONE. https://doi.org/10.1371/journal.pone.0210275

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.